

## TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1  
Stylesheet Version v1.2

ETAS ID: TM571172

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT		
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
<b>CONVEYING PARTY DATA</b>			
<b>Name</b>	<b>Formerly</b>	<b>Execution Date</b>	<b>Entity Type</b>
Intas Pharmaceuticals Limited		04/08/2020	Company: INDIA
<b>RECEIVING PARTY DATA</b>			
<b>Name:</b>	Accord Biopharma, Inc.		
<b>Street Address:</b>	1009 Slater Road, Suite 210		
<b>City:</b>	Durham		
<b>State/Country:</b>	NORTH CAROLINA		
<b>Postal Code:</b>	27703		
<b>Entity Type:</b>	Corporation: DELAWARE		
<b>PROPERTY NUMBERS Total: 3</b>			
<b>Property Type</b>	<b>Number</b>	<b>Word Mark</b>	
<b>Serial Number:</b>	87240794	GRAXOFIL	
<b>Serial Number:</b>	88260489	LAPELGA	
<b>Registration Number:</b>	5000903	GRASTOFIL	
<b>CORRESPONDENCE DATA</b>			
<b>Fax Number:</b>	7038164100		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
<b>Phone:</b>	7038164000		
<b>Email:</b>	sld@nixonvan.com		
<b>Correspondent Name:</b>	Sheryl De Luca		
<b>Address Line 1:</b>	901 N. Glebe Road, 11th Floor		
<b>Address Line 2:</b>	Nixon & Vanderhye P.C.		
<b>Address Line 4:</b>	Arlington, VIRGINIA 22203		
<b>NAME OF SUBMITTER:</b>	Sheryl De Luca		
<b>SIGNATURE:</b>	/Sheryl De Luca/		
<b>DATE SIGNED:</b>	04/09/2020		
<b>Total Attachments: 2</b>			
source=2020_04_08_14_23_53#page1.tif			
source=2020_04_08_14_23_53#page2.tif			

OP \$90.00 87240794

**TRADEMARK ASSIGNMENT**

This Trademark Assignment (this "Agreement"), is effective as of the last date below (the "Effective Date"), between Intas Pharmaceuticals Limited, a company of India having a principal place of business at Intas Corporate house, Near Sola Bridge, S.G. Highway, Thaltej, Ahmedabad, 380 054, Gujarat, India (hereinafter "ASSIGNOR"), and Accord Biopharma, Inc. a corporation of Delaware having its principle place of business at 1009 Slater Road, Suite 210, Durham North Carolina, 27703, U.S.A. (hereinafter "ASSIGNEE"). Assignor and Assignee are sometimes referred to collectively as the "Parties".

WHEREAS, ASSIGNOR is the owner of all right, title and interest to the trademarks in the attached Schedule A, the goodwill symbolized thereby and the United States Trademark Applications and Registrations for said marks (the "Trademarks");


WHEREAS, ASSIGNEE desires to acquire all of ASSIGNOR's rights, title and interest, goodwill symbolized thereby and the United States Trademark Applications and Registrations for the Trademarks;


NOW, THEREFORE, for and in consideration of the sum of Ten Dollars (\$10.00) and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

ASSIGNOR hereby sells, assigns, transfers and conveys to ASSIGNEE, its successors and assigns, all rights, title and interest in and to the Trademarks, the goodwill symbolized thereby, including the portion of ASSIGNOR's business to which the above-identified Trademarks pertain, and United States applications and registrations of said marks, together with the right to sue and obtain damages, injunctive relief and/or attorney's fees by reason of any and all past infringements of the mark, or for any other violation of any other rights in or relating to said marks.

INTAS PHARMACEUTICALS LIMITED

ACCORD BIOPHARMA, INC.

  
By: \_\_\_\_\_  
Name: Dr. Alpesh Pathak  
Title: Global IP Head  
Date: 8<sup>th</sup> April, 2020

  
By: \_\_\_\_\_  
Name: Shannon Price  
Title: Vice President  
Date: 4/8/20

SCHEDULE A

Registration/Application	Mark	Goods/Services
U.S. App. No. 87240794	GRAXOFIL	Biosimilar pharmaceutical preparation, namely, a granulocyte colony-stimulating factor analog used to stimulate the proliferation and differentiation of granulocytes for use with chemotherapy regimens to lessen the incidence of chemotherapy-induced neutropenia
U.S. App. No. 88260489	LAPELGA	Pharmaceutical preparations for hematopoietic growth factors; pharmaceutical preparations, namely, recombinant-human granulocyte-CSF for use in stimulating white blood cell production
U.S. Reg. No. 5000903	GRASTOFIL	Pharmaceutical preparations for [hemopoetic] *hematopoietic* growth factors; pharmaceutical preparations, namely, recombinant-human granulocyte-CSF for use in stimulating white blood cell production